Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL11222759 | 0.77 | MAPT (0.31) | — | |
| SCHEMBL30992162 | 0.75 | SLC6A3 (0.34) | SLC6A3SLC6A4 | |
| SCHEMBL25973802 | 0.75 | SLC6A4 (0.34) | SLC6A3SLC6A4 | |
| SCHEMBL24483580 | 0.75 | SLC6A4 (0.34) | SLC6A3SLC6A4 | |
| SCHEMBL24129062 | 0.75 | SLC6A4 (0.34) | SLC6A3SLC6A4 | |
| SCHEMBL10046777 | 0.73 | ALOX15 (0.41) | — | |
| SCHEMBL10084431 | 0.72 | — | — | |
| SCHEMBL7265074 | 0.72 | — | — | |
| SCHEMBL27504488 | 0.69 | — | — | |
| SCHEMBL5830838 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896036-B1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTPR LTD (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-8076323-B2 | Anti-inflammatory agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-12-13 | — | — | US | disclosed |
| US-20110003792-A1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
| US-7803794-B2 | Anti-inflammatory agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-20100016286-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-1896036-A1 | ANTI-INFLAMMATORY AGENTS | Cambridge Enterprise Limited (GB) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006134384-A1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016286-A1 | Anti-Inflammatory Agents | TNF, LTC4S, IL6 | SLC6A3 4139/4885SLC6A4 2680/4885 |
| US-20110003792-A1 | ANTI-INFLAMMATORY AGENTS | TNF, LTC4S, PTGS1 | SLC6A3 4212/4885SLC6A4 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.